Context Therapeutics Advances T-Cell Engager Pipeline with Three Bispecific Antibodies in Clinical Development
核心洞察
Context Therapeutics is advancing three T-cell engaging bispecific antibodies for solid tumors, with CTIM-76 showing preliminary anti-tumor activity and no dose-limiting toxicity in Phase 1 trials.
The company expects to report Phase 1a interim data for CTIM-76 in June 2026 and CT-95 in September 2026, with first patient dosing for CT-202 planned for Q3 2026.
Context maintains a strong financial position with $66.0 million in cash expected to fund operations into mid-2027, supporting multiple clinical milestones throughout 2026.
Context Therapeutics Inc. is positioning itself as a key player in the T-cell engaging bispecific antibody space with a robust pipeline of three candidates targeting solid tumors. The Philadelphia-based clinical-stage biopharmaceutical company reported significant progress across its portfolio in 2025, with multiple clinical readouts expected in 2026.
CTIM-76 Shows Early Promise in Phase 1 Trial
The company's lead candidate, CTIM-76, a Claudin 6 (搜索) x CD3 (搜索) T-cell engaging bispecific antibody, is currently in Phase 1 dose escalation for patients with ovarian, endometrial, or testicular cancer (搜索). In November 2025, Context presented encouraging early data from the first four cohorts of the ongoing Phase 1a study.
As of the October 30, 2025 data cutoff, 12 patients had received CTIM-76 treatment. The preliminary results showed signs of anti-tumor activity, including an ongoing RECIST response. Notably, no cytokine release syndrome greater than Grade 1 was observed across any cohort, and no dose-limiting toxicity had been reached, with the maximum tolerated dose yet to be established.
"We believe 2025 was a year of significant progress for Context as we advanced our pipeline of T cell-engaging bispecific antibodies for solid tumors," said Martin Lehr, CEO of Context. The company anticipates completing the weekly dose escalation phase in the first half of 2026 and plans to evaluate every three-week dosing in the second half of 2026.
Expanding Pipeline with CT-95 and CT-202
Context's second clinical-stage asset, CT-95, is a Mesothelin x CD3 (搜索) bispecific T-cell engager currently in Phase 1 dose escalation for patients with pancreatic, non-small cell lung, ovarian, mesothelioma (搜索), and colorectal cancers. The company is continuing dose escalation toward target dose levels and expects to provide Phase 1a interim data in September 2026.
The company's third candidate, CT-202, represents a novel approach to targeting Nectin-4 (搜索), a cell surface protein highly overexpressed in various solid tumors including bladder, colorectal, lung, and breast cancers. CT-202 is designed as a pH-dependent T-cell engager that preferentially activates within the tumor microenvironment, potentially addressing safety concerns associated with traditional Nectin-4-targeting antibody-drug conjugates, which have been linked to neuropathy and rash.
Context completed necessary regulatory filings for CT-202 in March 2026 and expects to dose the first patient in its Phase 1 trial during the third quarter of 2026. The company will present preclinical data for CT-202 at the American Association for Cancer Research Annual Meeting 2026, taking place April 17-22 in San Diego.
Strong Financial Position Supports Clinical Execution
Context reported cash and cash equivalents of $66.0 million as of December 31, 2025, compared to $94.4 million at the end of 2024. The company expects this funding to support operations into mid-2027, providing sufficient runway to deliver multiple clinical updates throughout 2026.
Research and development expenses increased to $31.9 million in 2025 from $22.7 million in 2024, primarily driven by higher CT-202 expenses of $4.4 million, increased CTIM-76 costs of $1.3 million, and higher personnel-related costs of $3.3 million. The company reported a net loss of $36.1 million for 2025, compared to $26.7 million in 2024.
Clinical Milestones on the Horizon
Context has outlined a clear timeline for clinical data releases across its pipeline. The company plans to host webinars to present CTIM-76 interim Phase 1a data in June 2026 and CT-95 interim Phase 1a data in September 2026. These presentations will provide critical insights into the safety and efficacy profiles of the company's T-cell engaging platform.
"Supported by an expected cash runway extending into mid-2027, we remain focused on execution and believe we are positioned to deliver multiple clinical updates throughout the remainder of 2026," concluded CEO Martin Lehr.
The company's approach to T-cell engaging bispecific antibodies represents a growing area of interest in oncology, as these therapies aim to redirect patient T-cells to recognize and eliminate cancer cells while potentially offering improved safety profiles compared to traditional cancer immunotherapies.